Earnings Releases·Nov 12, 2026, 4:10 PM ET

Relmada Therapeutics — Third Quarter 2026 Earnings Summary

Net loss for the three months ended September 30, 2026, was $13.9 million ($0.12 per share), compared to $10.1 million ($0.30 per share) in the prior year period, while R&D expenses rose to $9.2 million from $4.0 million.
Cash, cash equivalents, and short-term investments increased to $202.1 million as of September 30, 2026, from $93.0 million at year-end 2025, providing sufficient funding to support operations through 2029 including the completion of the NDV-01 Phase 3 SPECTRUM program.
The NDV-01 CMC program remains on track for an IND submission by year-end 2026, with Phase 3 SPECTRUM initiation expected upon clearance and updated 18-month durability data showing 86% of evaluable patients remained in complete response.
The company received written FDA feedback confirming alignment on two independent registrational pathways for NDV-01 in non-muscle invasive bladder cancer, and the Phase 3 program was renamed SPECTRUM to reflect its breadth across the disease spectrum.